Pfizer Inc. (PFE) to Distribute Quarterly Dividend of $0.43 on September 1st

Pfizer Inc. (NYSE:PFE) declared a quarterly dividend on Wednesday, June 24th. Shareholders of record on Friday, July 24th will be paid a dividend of 0.43 per share by the biopharmaceutical company on Tuesday, September 1st. This represents a c) dividend on an annualized basis and a yield of 6.9%. The ex-dividend date is Friday, July 24th.

Pfizer has decreased its dividend by an average of 0.1%per year over the last three years and has increased its dividend annually for the last 16 consecutive years. Pfizer has a payout ratio of 55.8% indicating that its dividend is sufficiently covered by earnings. Analysts expect Pfizer to earn $2.85 per share next year, which means the company should continue to be able to cover its $1.72 annual dividend with an expected future payout ratio of 60.4%.

Pfizer Stock Up 0.6%

Pfizer stock opened at $24.91 on Wednesday. The company has a 50 day moving average of $25.17 and a 200-day moving average of $26.18. The company has a quick ratio of 0.94, a current ratio of 1.25 and a debt-to-equity ratio of 0.67. Pfizer has a twelve month low of $23.11 and a twelve month high of $28.75. The stock has a market capitalization of $141.97 billion, a PE ratio of 19.02 and a beta of 0.35.

Pfizer (NYSE:PFE) last issued its quarterly earnings data on Tuesday, May 5th. The biopharmaceutical company reported $0.75 EPS for the quarter, topping analysts’ consensus estimates of $0.72 by $0.03. The business had revenue of $14.45 billion for the quarter, compared to analyst estimates of $13.84 billion. Pfizer had a net margin of 11.83% and a return on equity of 19.44%. The firm’s quarterly revenue was up 5.4% on a year-over-year basis. During the same period last year, the business posted $0.92 earnings per share. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. On average, equities research analysts anticipate that Pfizer will post 2.96 EPS for the current fiscal year.

Pfizer News Roundup

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Pfizer could benefit from strength in key non-oncology drugs, with Eliquis and Vyndaqel expected to post better Q2 sales, which may help offset declines elsewhere in the portfolio. What to Watch in Pfizer’s Non-Oncology Portfolio This Earnings Season
• Positive Sentiment: Pfizer is drawing interest as a potential winner in the large weight-loss drug market, supporting longer-term growth expectations if it can compete successfully. Could Pfizer Ultimately Be the Biggest Winner in the $100 Billion Weight-Loss Market?
• Neutral Sentiment: Pfizer remains one of the more watched healthcare names among investors, suggesting the stock may see ongoing trading interest ahead of earnings and new updates. Is Trending Stock Pfizer Inc. (PFE) a Buy Now?
• Neutral Sentiment: Recent commentary compared Pfizer with other sub-$50 stocks, but the note was mainly a general screening piece rather than a company-specific catalyst. 1 Stock Under $50 to Target This Week and 2 We Question
• Negative Sentiment: Pfizer faces new international patent lawsuits from Arbutus Biopharma and Genevant Sciences over its mRNA COVID-19 vaccines, creating potential damage claims and injunction risk. Pfizer (PFE) Faces New International Patent Lawsuits Over Covid 19 Vaccine
• Negative Sentiment: COVID-related product sales are expected to decline, which may weigh on quarterly results and reinforce concerns about shrinking pandemic-era revenue streams. What to Watch in Pfizer’s Non-Oncology Portfolio This Earnings Season

Pfizer Company Profile

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.